Additionally, in a case series of seven DLBCL patients who progressed after CAR-T and subsequently received chidamide (a histone deacetylase inhibitor [HDACi]) plus sintilimab, two patients achieved CR, and CR patients were not PD-L1 over-expressed (Hao et al., 2022). This evidence concerns the gene CD274 and diffuse large B-cell lymphoma.